Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth
Authors
Keywords
-
Journal
PROSTATE
Volume 80, Issue 1, Pages 88-98
Publisher
Wiley
Online
2019-10-29
DOI
10.1002/pros.23921
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer
- (2018) Hiroshi Hongo et al. CANCER SCIENCE
- SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins
- (2018) Su Yan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy
- (2018) Yasuomi Shimizu et al. Journal of Clinical Medicine
- Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5
- (2017) Waseem Al-Jameel et al. Oncotarget
- Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer
- (2017) Kazutoshi Fujita et al. Scientific Reports
- Sleeping Beautyscreen revealsPpargactivation in metastatic prostate cancer
- (2016) Imran Ahmad et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter
- (2016) Farzad S. Forootan et al. Oncotarget
- The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells
- (2016) Reem T. Attia et al. PeerJ
- The cancer-promoting gene fatty acid-binding protein 5 (FABP5) is epigenetically regulated during human prostate carcinogenesis
- (2015) K. Kawaguchi et al. BIOCHEMICAL JOURNAL
- Current and Emerging Therapies for Bone Metastatic Castration-Resistant Prostate Cancer
- (2015) Jeremy S. Frieling et al. Cancer Control
- Inhibition of Fatty Acid Binding Proteins Elevates Brain Anandamide Levels and Produces Analgesia
- (2014) Martin Kaczocha et al. PLoS One
- The fat side of prostate cancer
- (2013) Giorgia Zadra et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Optimal management of patients receiving cabazitaxel-based chemotherapy
- (2013) Catherine Sperlich et al. CUAJ-Canadian Urological Association Journal
- The expression of C-FABP and PPARγ and their prognostic significance in prostate cancer
- (2013) FARZAD S. FOROOTAN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes
- (2012) Claire Corcoran et al. PLoS One
- Targeting Fatty Acid Binding Protein (FABP) Anandamide Transporters – A Novel Strategy for Development of Anti-Inflammatory and Anti-Nociceptive Drugs
- (2012) William T. Berger et al. PLoS One
- New and emerging agents for the treatment of castration-resistant prostate cancer
- (2011) Celestia S. Higano et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
- (2011) Emmanuel Antonarakis et al. Drug Design Development and Therapy
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Docetaxel-related side effects and their management
- (2009) Jackie Baker et al. European Journal of Oncology Nursing
- Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets
- (2008) Masato Furuhashi et al. NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started